Evidence
What Actually Happens When You Stop Tirzepatide
SURMOUNT-4 answered this directly. After a 36-week open-label lead-in in which everyone lost weight on tirzepatide, 670 adults were randomised to continue or switch to placebo for 52 weeks. Those who continued maintained and slightly extended their loss. Those who stopped regained substantially. Regain is the expected physiological outcome, not a failure of willpower.
Key takeaways
- SURMOUNT-4 used a randomised withdrawal design, which isolates the effect of stopping.
- Everyone lost weight on the drug first, so the groups were comparable at randomisation.
- Continuing maintained the loss; switching to placebo produced substantial regain.
- Regain reflects the return of appetite signalling once the drug clears.
- This is why cost should be modelled over years rather than months.
| Trial | SURMOUNT-4 |
|---|---|
| Design | Randomised withdrawal after 36-week lead-in |
| Participants | 670 |
| Follow-up | 52 weeks after randomisation |
| Finding | Substantial regain on placebo; maintenance on continued treatment |
| Identifiers | NCT04660643 · PMID 38078870 · doi:10.1001/jama.2023.24945 |
Why is this design more persuasive than follow-up studies?
Observational reports of regain can always be explained away by selection: perhaps the people who stopped were struggling anyway. SURMOUNT-4 removes that objection entirely. Every participant had already lost weight on tirzepatide before randomisation, so the two groups were comparable at the moment they diverged.
What follows the split is therefore attributable to the withdrawal itself rather than to differences between the people in each arm.
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 52 |
|---|---|---|---|---|---|
| Continued tirzepatide | 0% | -1.1% | -1.9% | -2.4% | -2.6% |
| Switched to placebo | 0% | 3.9% | 7.6% | 10.5% | 12.2% |
Does everyone regain everything?
No, and the trial does not claim that. Regain was substantial on average but incomplete within the 52-week window, and it varied between individuals. What the data does not support is the expectation that stopping preserves the result.
Nor does it establish where regain plateaus, because the trial did not run long enough to find out. Anyone quoting a precise percentage regained by a precise month is extrapolating past the evidence.
Why does the framing matter clinically?
Because calling regain a relapse discourages honest conversation. Someone who believes it reflects personal failure is less likely to tell a prescriber they stopped, less likely to discuss restarting, and more likely to try something unsupervised.
The randomised evidence contradicts that framing directly. Participants regained after being assigned to stop, with nothing about their motivation changing at the moment of randomisation.
What does this mean financially?
It converts tirzepatide from a course into a standing cost. If maintaining the result generally requires continued treatment, then an introductory discount is close to irrelevant and the recurring price is nearly everything. Model two to three years at the maintenance-dose price before starting, not one month at the promotional rate.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on stopping tirzepatide weight regain.
- A change to FDA labelling or regulatory position affecting a statement above.
- A verified correction accepted through the corrections process.
- A material change to a captured price, term, or programme condition.
More from the journal: all pieces
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- New primary evidence bearing directly on what actually happens when you stop tirzepatide.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including DOI, PMID, open-label, placebo — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| open-label | A trial in which participants and investigators know which treatment is being given. SURMOUNT-5 was open-label, a genuine limitation, though weight is an objective measurement less vulnerable to expectation than a self-reported outcome. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised withdrawal | A design in which everyone first receives the active drug, and only those who respond are then randomised to continue or stop. SURMOUNT-4 used this design, which is why its regain finding cannot be explained away by differences between groups. |
Frequently asked questions
Will I regain weight if I stop tirzepatide?
Substantial regain followed randomised withdrawal in SURMOUNT-4. Individual results vary, but maintaining the loss generally requires continued treatment.
How fast does regain happen?
It accumulated over the 52-week withdrawal period. The trial does not support a precise personal timeline.
Is there a way to taper that prevents regain?
No trial cited here establishes that any particular way of stopping produces a better outcome. This site publishes no tapering schedule.
Can a lower maintenance dose hold the result?
SURMOUNT-MAINTAIN answered it. Reducing to 5 mg maintained -16.6% bodyweight reduction versus -21.9% on the maximum tolerated dose and -9.9% on placebo (SURMOUNT-MAINTAIN, Lancet 2026).
Does this mean the drug did not work?
The opposite. Participants had already lost weight on it; withdrawal removed the mechanism producing that effect.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.